Thanks, Andy.
As quarter second the accomplishments we Today, the will the has think Bio. the the operating we and call, since business seven I Vyant merger. made begin was as important of that progress one the highlight I our is to our have full half everyone it’s quarter remind closing company third operated months and in
indications. Bio molecule treat an discovery identifying therapeutics sector, nervous to use unique diseases. creation neurological in emerging patients and discovery and to identify and drug We the drivers to have insightful believe savings, making treat oncology-related We was repositioned with system cost global oncological therapeutics targets biological and discovery to drive and our speed, focused company, engine Vyant small to and novel decision are large acute on intend drug we there central value significant
the We today. like few you for I’d we to have progress, third begin, highlights recap will promising made To non-financial which a from highlight quarter.
scientific and hired Dr. IND brings discovering drug experience he’s already discovery on decades record candidate drug as joined ago we in over track therapeutics. a invaluable proven and to driving further for proof-of-concept. the and recognized efforts internationally. us portfolio discovery translational develop of to research our weeks next disorders including two strategy and neuroscience therapeutic preclinical our few submissions. He scientific experience of with we impact and neurological academia novel in meaningful programs and disease industry a will as and all expertise Fremeau’s lead companies, Jr. efforts, human severe complete indications. First, T. discovery our on The feasibility discovery to generation having a way in drug excellence drug with biopharma be Robert to CSO Fremeau has of extensive development leading candidates the focusing Dr. with our us Fremeau, a from identification target, lead early
biopharma running development, long leveraged regard, completion programs from will infrastructures, further we points the will with While support initial a partners. partnerships announce drug derived building all discovery. agreement, next engagement analytics biopharmaceutical, few show this and of to the co-development evidenced experience Therapeutics We term result MASORI Therapeutics. Japan companies We platform Bio’s worked including is track in programs, MASORI jointly this believe with partnering pharmaceutical are make to focused validation MASORI and biology biotechnology in by yet we advanced our are are and focused that in licensing into The to concept two entered activities drive we U.S. company that have progress areas with team a with of proof of potential technology co-development to has partnerships MASORI continuing licensing successful feasibility these being into conjunction announced additional entered our and record shape the of weeks marketing in with our consummation. and with potential efforts, we or pursue collaboration in out Vyant and industry. a commercial biopharma ago, human with these drug on discovery and decades partnerships Tokyo-based taking early complex partnership in other pharmaceutical To year. and we to a
on model and internal have investigation of progress discovery of efforts, deeper making compound development disease toxicity. their terms lead and our continue efficacy and compounds we our In
biological action. compounds, In addition, into we are investigation of lead potential of the deep the specific mechanisms basis of
expansion and compounds. include disease two a completed conjunction in novel These large hit across with Rett we biological screening collaboration yielding the further compounds novel targets AI-generated Atomwise, for results. Additionally, partner second promising our unique of program results several
compounds through be data lead begun to our collaboration continues validate lead Cyclica CDKLX with and data of our a of X,XXX alongside proteome-wide, complex to the hit will treatments create then show with clinical in Deficiency comparative positively animal and recently narrowing safety agreement a indication additional to efficacy Our run new some ran on are Artificial to moving over identify Vyant further screen To screenings Syndrome Disorder. identification. process. to and patient-derived we about Bio’s to have discovery Cyclica’s into Rett for Intelligence validation Also platform our optimization additional Rett organoid modeling, model, we biology disease concordance data QX, entered enabled iterate program combining
made note, of Initially, variability established and platform epilepsy advance art we optimized and readouts. the further the developed our our state of program. neuronal genetic in characterize to further disease internal micro We CDKLX it and phenotypes. significant assays brain to different that we adapt progress specific portfolio etiology On have to minimize the
as screenings we library, Bio Additionally, for and designed a for X,XXX clinical compounds this more Vyant compounds the disease category. compounds recover targets we most relevance to defined as phenotypic the customized phenotype of CDKLX that have extensive CDKLX. proven potential our well than low Using library focusing toxicity well molecular on novel relevant high leading with performed with many identifying one functional mechanistic
on The for Cyclica’s internal collaboration evaluation new Ordaōs also proteome-wide and remains based identified Cellaria schedule. and further we targets Bio learning on machine Finally, expertise. platform our
only we introduce has assessed not been and the additional drug rapidly likely Artificial candidates updated patient neural include of in numerous design, successful process The have state-of-the-art design announced, avatar optimize to collaboration specific it structure efficacy be clinic. of goal to candidates, are in cell in-silico based drug trials, vitro intended to As recurrent a Intelligence also The network model even is to collaboration for biological to protein before is but they mechanisms. cell-based discovery new using previously clinical and to this the attention trials. with patient redesign clinical incorporation making been in design
addition, binding these production in-silico XX novel of have sequences. has Financial proof-of-functionality third to the in will financial assays improvements coming I Andy? the on quarter. In basis the Protein to million for than for call results protein further These the for sequences. the model over will second further will Officer been and now a begin turn novel designs discuss formed protein Andy round shortly Chief on the trained our more functional and follow month. LaFrence,
